• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

    5/1/24 5:14:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email

    BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innovatively invented a new natural active water-soluble product extracted from soybean gum. Pure physical extraction technology of natural active phospholipids - Large column chromatography polar ultrafiltration membrane pure physical extraction technology has achieved an innovative breakthrough in pure physical extraction technology of natural active phospholipids, overcoming the current chemical solvent extraction method from soybean gum at high temperature Dehydrated to concentrated phospholipid oil, separated and extracted by chemical solvents such as hexane, acetone, methane, etc., and then evaporated and desolvated at high temperature. During the production process, oxidation reactions, hydrolysis reactions, polymerization reactions, chelation reactions, etc. will occur, leading to destruction and change of the natural structure of phospholipids. and a variety of active functional groups, resulting in the inactivation or weakening of the activity of phospholipids. In addition, the existing pure physical extraction techniques to extract natural active phospholipids are extremely costly and can only be applied in scientists' laboratories and cannot achieve large-scale mass production. We have successfully developed and produced natural water-soluble phospholipids with high hydrophilicity, high activity, high purity, and high absorption and utilization by the human body. The first batch of products will be successfully put into production at the Kaifeng production base in April 2024. Phospholipid supplementation is a difficult problem in cellular nutrition worldwide.

    Modern biomedical research has confirmed that there are more than 50,000 human diseases discovered so far, and the origin of the disease is cell problems. Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body. Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities. When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health. On the contrary, if cell nutrition is insufficient or imbalanced, the normal function of cells will be affected, which may lead to cell damage, aging and even death.

    Among the nutrients that are indispensable for human cells, proteins, carbohydrates, fats, vitamins, minerals, dietary fiber, water, etc., if they are lacking, they are usually supplemented by the scientific method of "daily food + nutritional preparations". Proteins, carbohydrates, fats, dietary fiber and other nutritional products are becoming increasingly mature from theoretical research to production technology. Industrial mass production has no technical problems. From clinical medical nutrition to sub-health, nutritional conditioning for post-illness rehabilitation to healthy people Daily nutrition improves health. Patients, convalescents, and people in sub-healthy conditions who lack these nutrients can easily obtain supplements through food plus various nutritional preparations such as industrially produced nutritional drugs and functional foods.

    Phospholipids exist in any cell in the human body and are the main component of cell membranes (40%). They account for 40% of the dry matter of the brain, 40% of the dry matter of bone marrow, and 25% of the total lipids in the blood. The mitochondria and Golgi inside the cells Both bodies and microsomes have high concentrations of phospholipids. Phospholipids have an amphipathic structure, a bilayer structure in the water phase, and a variety of unique physiological functions. As a functional nutrient for human cells, phospholipids not only build cell membranes and organelle membranes to maintain the stability and dynamic fluidity of cells and organelles, but phospholipid molecules also enter Organelles, as well as on cell membranes and organelle membranes, interact with a variety of proteins, enzymes, and other molecules, participate in a variety of physiological processes, regulate and participate in material and energy metabolism, signal transduction, and antioxidant, affecting cell growth, differentiation, Life activities such as apoptosis often have the characteristics of multi-targets, multi-mechanisms, multi-pathways and multi-functions, and play an overall role. Compared with other cellular nutrients, phospholipids have unique, critical and irreplaceable functions within cells.

    Excessive consumption, malabsorption, chronic diseases, inflammation, frequent sexual life, skin damage, pregnancy and postpartum, surgery, growth and development, excessive brain use, etc. lead to phospholipid deficiency in human cells.

    The human body can synthesize a small amount of phospholipids in the body, but it cannot meet all the body's needs for phospholipids. Especially with age, the body's own ability to synthesize phospholipids gradually weakens, and most phospholipids require exogenous intake, such as food and nutritional preparations.

    Supplementing the phospholipids that the human body lacks is a difficult problem in cell function nutrition in today's world.

    Adults can take 3000-3700mg of natural active phospholipids per day, supplemented through food, which is equivalent to up to 30 eggs per day. Typically each egg yolk contains about 100-120 mg of phospholipids. So 30 egg yolks contain approximately 3000-3600 mg of phospholipids. This is an astonishing number! What is even more troubling is that during food cooking and processing, the natural amphiphilic structure and various active functional groups of phospholipids are damaged by high temperatures, which will be affected by high temperatures, resulting in a reduction or loss of their activity. Moreover, our bodies cannot digest and absorb such large amounts of food efficiently.

    Because the chemical solvent extraction method has obvious advantages such as low raw material requirements, simple and mature equipment and processes, high efficiency, and low cost, as well as multiple chemical purifications, it can also obtain high-purity phospholipids, and chemical modification can obtain special properties and functional phospholipids. It is convenient and has become the mainstream technology for industrial extraction and production of natural phospholipids.

    The raw materials of phospholipid nutraceuticals, functional foods and other preparations currently on the market are extracted by chemical solvent extraction. Because the natural native parent parent structure and activity of phospholipids are destroyed, their effectiveness is far from the natural active phospholipids extracted by physical methods. Consumers Users may also have safety concerns.

    Natural active phospholipids can only be obtained through pure physical extraction. The pure physical extraction technology of natural active phospholipids is a cutting-edge technology. Compared with traditional chemical extraction methods, it avoids the use of chemical solvents and retains the original biological activity, structure and structure of natural phospholipids. The function has unique advantages and meets the needs of medicine, functional food, and beauty and skin care products for highly active, high-purity, and high-quality phospholipids.

    The purely physical extraction technology has complicated processes, low extraction efficiency, extremely high cost, small scale, and cannot leave the laboratory. The large-scale mass production of natural active phospholipids extracted by purely physical methods is a global problem.

    The pure physical extraction technology of large column chromatography polar ultrafiltration membrane innovatively invented by Shanggao Company has great advantages compared with other pure physical technologies such as carbon dioxide supercritical fluid extraction and ultrasonic-assisted extraction. The raw material is fresh soybean gum. The whole process is protected by inert gas and the temperature is controlled below 80°C. No chemical solvents are involved in the whole process. 80% aqueous solution is used as the solvent (similar to the water content of the human body) to reduce the orderly arrangement of phospholipid molecules. The natural state protects the natural structure and activity of phospholipids to the greatest extent and avoids various chemical reactions that damage and change the original structure and biological activity of phospholipids. At the same time, unlike other purely physical methods that require multiple separations and extractions, the process is complicated, the extraction efficiency is low, and the cost is extremely high. It cannot be applied to industrial-scale mass production and can only be applied in laboratories, which cannot escape the limitations of small-scale preparation. Utilizing specific structured phospholipid characteristics, through precise parameter design and regulation and a special ultrafiltration membrane structure, one-time precise separation and extraction is achieved, which greatly improves the separation and extraction efficiency and yield, and greatly reduces the cost. The purity of phospholipids can reach more than 99% after one-time extraction, the average PC content of and the PC content after purification reaches more than 90%.

    As an important and irreplaceable physiologically active functional substance for human cells, phospholipids have multiple pharmacological effects. The highly active and high-purity natural water-soluble phospholipids extracted by purely physical methods provide new possibilities for the research and development of new drugs. Providing new treatment methods and means is of extremely high value in the field of medical medicine.

    At the same time, phospholipids serve as drug carriers, wrapping drugs in phospholipid bilayer vesicles, and achieving targeted delivery of drugs through the fusion of cell membranes. This kind of delivery is highly selective and effective, can effectively improve the bioavailability and targeting of drugs, and reduce the side effects of drugs. It has shown remarkable efficacy in anti-tumor, anti-Alzheimer's disease, anti-virus and other fields.

    The bioimaging function of phospholipids also provides new means for disease diagnosis and treatment.

    Phospholipids have excellent moisturizing, antioxidant and anti-aging effects. Natural active water-soluble phospholipids extracted by purely physical methods will be able to produce more effective, safe and high-end products in the field of beauty and skin care products.

    In the field of cell function nutritional supplements, it will promote product upgrading and is in line with the main theme of natural, green and healthy, and is bound to become a super new category of comprehensive health products.

    3.85 billion years ago, a 50-million-year-old heavy rain fell on the earth, and phospholipids were born in the water. Phospholipids and water jointly created the original vesicle membrane structure of life cells, ushering in the evolution of life on earth. It has been nearly a hundred years since humans discovered soybean phospholipids, a nutritional treasure of cellular functions, in 1930. Pure physical methods have been used to extract natural active phospholipids from soybeans. From the shining scientific theories and the laboratories of temple-like scientists, because of Dazhu The invention and application of purely physical extraction technology of chromatographic polar ultrafiltration membranes has come to large-scale mass production factories, and a century-old ideal has been realized, and finally the natural activity and water solubility of Meierdashan have been presented in a natural state. In front of mankind, natural active water-soluble phospholipids can finally benefit the world. People finally have truly natural active water-soluble phospholipids in medicines and functional foods. It solves the two major world problems of "difficulty in replenishing phospholipids" and "difficulty in pure physical extraction of natural active phospholipids".

    For the natural active water-soluble phospholipid project, Shanggao Company and its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. will use the establishment of a core value chain as their basic strategy, focusing on drugs, functional foods, and beauty and skin care products. The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry. Annual sales revenue is expected to reach $1 billion within three years.

    About Shineco, Inc.

    Shineco Inc. ("Shineco" or the "Company") aims to 'care for a healthy life and improve the quality of life', by providing safe, efficient and high-quality health and medical products and services to society. Shineco, operating through subsidiaries, has researched and developed 33 vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious foods. For more information about Shineco, please visit www.biosisi.com/.

    Forward-Looking Statements

    This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may", "will", "should", "could", "intend", "expect", "plan", "budget", "forecast", "anticipate", "believe", "estimate", "predict", "potential", "continue", "evaluating" or similar words. Forward-looking statements should not be relied upon because they are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Examples of forward-looking statements include, among others, statements we make regarding the innovativeness and market position of our products and services, our competitive strengths, and our expectation that the healthy meals replacement joint venture will be a competitive products in its field. You are cautioned not to rely on any forward-looking statements. Actual results may differ materially from historical results or those indicated by the forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company's ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the ability to obtain all necessary regulatory approvals in the jurisdictions where it intends to market and sell its products the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulations, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and speak only as of the date of this press release, and Shineco assumes no obligation to update any forward-looking statements except as required by the applicable rules and regulations.

    For more information, please contact:

    Shineco,Inc.

    [email protected]

    Mobile: +86-010-68130220

    Precept Investor Relations LLC

    David J. Rudnick

    [email protected]

    Mobile: +1-646-694-8538

     

    Cision View original content:https://www.prnewswire.com/news-releases/shineco-develops-revolutionary-new-product-with-varied-applications-to-positively-impact-the-health-care-industry-302132880.html

    SOURCE Shineco,Inc.

    Get the next $SISI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

    BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad

    9/12/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

    BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical suppor

    9/10/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

    BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agree

    8/27/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    SEC Filings

    View All

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - SHINECO, INC. (0001300734) (Filer)

    10/8/25 3:30:52 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form NT 10-K filed by Shineco Inc.

    NT 10-K - SHINECO, INC. (0001300734) (Filer)

    9/29/25 6:15:10 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - SHINECO, INC. (0001300734) (Filer)

    7/30/25 7:35:46 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

    3 - SHINECO, INC. (0001300734) (Issuer)

    4/24/25 4:05:15 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Yan Chi Keung

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Wang Xiaohui

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:16 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    View All

    Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

    BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. The Division is expected to use blockchain technol

    8/13/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Future FinTech Announces the Appointment of Hu Li as the New CEO

    NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

    8/9/24 9:00:00 AM ET
    $FTFT
    $SISI
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Announces the Appointment of Two New Executive Officers

    BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

    11/17/23 9:00:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Shineco Inc.

    SC 13G/A - SHINECO, INC. (0001300734) (Subject)

    10/25/24 2:45:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Shineco Inc.

    SC 13D - SHINECO, INC. (0001300734) (Subject)

    7/12/24 5:28:03 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Shineco Inc.

    SC 13G - SHINECO, INC. (0001300734) (Subject)

    8/29/23 1:26:38 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care